FORTIVE

Discussion in 'Johnson & Johnson' started by anonymous, Oct 29, 2018 at 11:20 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    ASP will be transitioning to Fortive very soon. . . any thoughts or insights?
     

  2. anonymous

    anonymous Guest

    Great question.
     
  3. anonymous

    anonymous Guest

    My take away is if your work on instruments you are in trouble or if you work in CSS in general (minus Biosense Webster). I think its pretty obvious JnJ does not care about Acclarent, Mentor, or instrument portfolios based off of recent moves. (Synthes/Ethicon selling mfg to Jabil and DePuy Power Tools getting its own president). Typically when you have your own president and are being run separate of MDD your getting shit canned.
     
  4. anonymous

    anonymous Guest

    They've been trying to sell power tools for a few years.
     
  5. anonymous

    anonymous Guest

     
  6. anonymous

    anonymous Guest

    I think the originator of the thread meant FORTIS.
     
  7. anonymous

    anonymous Guest

    No dumba$$, it's Fortive.

    Fortive is known for extremely lean operations. They are going to cut a lot of fat & bloated overhead once they take control of ASP next year.
     
  8. anonymous

    anonymous Guest

    They won’t have any trouble finding fat....
     
  9. anonymous

    anonymous Guest

    What I find very interesting about the Fortive acquisition of ASP is that Shlomi came in and sold the company to people who have a similar personal background and heritage. Check out Shlomi's bio and check out the bios of the brothers who started Fortive. Wonder if everything was above board. ASP was a textbook example of plundering a company that was making money so it could be sold off for a song.
     
  10. anonymous

    anonymous Guest

    Shlomi sells everything to fund his child Biosense. He sold Cordis, Codman, & ASP to raise billions to pour into Biosense. Now he's going to sell Acclarent & Mentor next, then he will sell Vision Care.
     
  11. anonymous

    anonymous Guest

    buying all those companies (except Vistakon) was a big mistake anyway but Schlomo thinks easier to sell than fix
     
  12. anonymous

    anonymous Guest

    cat
     
  13. anonymous

    anonymous Guest

    prepare for a mass exodus...
     
  14. anonymous

    anonymous Guest

    nothing happened
     
  15. anonymous

    anonymous Guest

    Vision Care is performing phenomenally. No chance it is getting sold off.
     
  16. anonymous

    anonymous Guest

    Just wait for 1 bad year of sales with sub-par growth below 4%, McKinsey will be on the phone on a daily basis with Goldman Sachs and BofA to dump the business.
     
  17. anonymous

    anonymous Guest

    Has Fortive figured out they bought a lemon yet?
     
  18. anonymous

    anonymous Guest

    heads are rolling.. more changes to come soon
     
  19. anonymous

    anonymous Guest

    heads rolling is questionable.
     
  20. anonymous

    anonymous Guest

    just wait until next quarter